10-Q quarterly report · filed Nov 5, 2026

Zenas BioPharma, Inc. (ZBIO) Q3 2026 10-Q Quarterly Report

Short answer

Zenas BioPharma, Inc. (ZBIO) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $10M with net income of −$109M.

Q3 2026 key financials · XBRL

Revenue
$10M
Net income
−$109M
−111.5% YoY · +2.3% QoQ
Operating margin
-1034.1%
EPS (diluted)
−$1.67
−36.9% YoY · +6.2% QoQ

Source: XBRL data from the Zenas BioPharma, Inc. (ZBIO) Q3 2026 10-Q on SEC EDGAR. USD.

Zenas BioPharma, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $10.0M, up from $0, driven by BMS development and regulatory milestone
  • Net loss $108.9M vs $51.5M YoY, operating margin -1,034.1% vs not meaningful
  • R&D $58.5M, led by obexelimab $22.6M and orelabrutinib $12.9M
  • Cash, equivalents and investments $647.1M, operating cash outflow $190.4M for nine months
  • Outlook: cash runway into 2029, with SLE topline results expected Q4 2026 and tariff-related cost headwinds

Risk Factors

  • New regulatory risk: April 2026 U.S. tariffs on patented pharmaceutical products, potentially increasing imported obexelimab costs
  • China supply-chain exposure: WuXi Biologics remains sole obexelimab CMO, with imports subject to existing tariffs
  • Debt-servicing risk: Operations are not expected to generate sufficient cash flow to service debt and fund capital expenditures
  • Convertible-note liquidity risk: Required cash settlements upon conversion could materially reduce liquidity
  • Maturity risk: Loan Agreement matures in 2031, requiring refinancing or repayment capacity then

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Zenas BioPharma, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.